These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17495127)

  • 1. CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
    Nakao K; Murase A; Ohshiro H; Okumura T; Taniguchi K; Murata Y; Masuda M; Kato T; Okumura Y; Takada J
    J Pharmacol Exp Ther; 2007 Aug; 322(2):686-94. PubMed ID: 17495127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP(4) receptor antagonist.
    Murase A; Taniguchi Y; Tonai-Kachi H; Nakao K; Takada J
    Life Sci; 2008 Jan; 82(3-4):226-32. PubMed ID: 18155068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of prostanoid EP4 receptor antagonist, CJ-042,794, in rat models of pain and inflammation.
    Murase A; Okumura T; Sakakibara A; Tonai-Kachi H; Nakao K; Takada J
    Eur J Pharmacol; 2008 Feb; 580(1-2):116-21. PubMed ID: 18031725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral prostaglandin E2 prolongs the sensitization of nociceptive dorsal root ganglion neurons possibly by facilitating the synthesis and anterograde axonal trafficking of EP4 receptors.
    St-Jacques B; Ma W
    Exp Neurol; 2014 Nov; 261():354-66. PubMed ID: 24910202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.
    Gavva NR; Tamir R; Qu Y; Klionsky L; Zhang TJ; Immke D; Wang J; Zhu D; Vanderah TW; Porreca F; Doherty EM; Norman MH; Wild KD; Bannon AW; Louis JC; Treanor JJ
    J Pharmacol Exp Ther; 2005 Apr; 313(1):474-84. PubMed ID: 15615864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity.
    Lin CR; Amaya F; Barrett L; Wang H; Takada J; Samad TA; Woolf CJ
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1096-103. PubMed ID: 16966471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
    Davis TL; Sharif NA
    Br J Pharmacol; 2000 Aug; 130(8):1919-26. PubMed ID: 10952683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E(2) increases cyclic AMP and inhibits endothelin-1 production/secretion by guinea-pig tracheal epithelial cells through EP(4) receptors.
    Pelletier S; Dubé J; Villeneuve A; Gobeil F; Yang Q; Battistini B; Guillemette G; Sirois P
    Br J Pharmacol; 2001 Mar; 132(5):999-1008. PubMed ID: 11226130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MF498 [N-{[4-(5,9-Diethoxy-6-oxo-6,8-dihydro-7H-pyrrolo[3,4-g]quinolin-7-yl)-3-methylbenzyl]sulfonyl}-2-(2-methoxyphenyl)acetamide], a selective E prostanoid receptor 4 antagonist, relieves joint inflammation and pain in rodent models of rheumatoid and osteoarthritis.
    Clark P; Rowland SE; Denis D; Mathieu MC; Stocco R; Poirier H; Burch J; Han Y; Audoly L; Therien AG; Xu D
    J Pharmacol Exp Ther; 2008 May; 325(2):425-34. PubMed ID: 18287210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostaglandin receptor subtypes, EP3C and EP4, mediate the prostaglandin E2-induced cAMP production and sensitization of sensory neurons.
    Southall MD; Vasko MR
    J Biol Chem; 2001 May; 276(19):16083-91. PubMed ID: 11278900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E(2) couples through EP(4) prostanoid receptors to induce IL-8 production in human colonic epithelial cell lines.
    Dey I; Giembycz MA; Chadee K
    Br J Pharmacol; 2009 Feb; 156(3):475-85. PubMed ID: 19175605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spinal EP receptors mediating prostaglandin E2-induced mechanical hyperalgesia, thermal hyperalgesia, and touch-evoked allodynia in rats.
    Mebane H; Turnbach ME; Randich A
    J Pain; 2003 Sep; 4(7):392-9. PubMed ID: 14622681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive and antihyperalgesic effects of tapentadol in animal models of inflammatory pain.
    Schiene K; De Vry J; Tzschentke TM
    J Pharmacol Exp Ther; 2011 Nov; 339(2):537-44. PubMed ID: 21816956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
    Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
    Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a novel selective agonist for prostaglandin receptor subtype EP4 on hyperalgesia and inflammation in monoarthritic model.
    Omote K; Kawamata T; Nakayama Y; Yamamoto H; Kawamata M; Namiki A
    Anesthesiology; 2002 Jul; 97(1):170-6. PubMed ID: 12131119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of peripheral administration of a novel selective antagonist for prostaglandin E receptor subtype EP(1), ONO-8711, in a rat model of postoperative pain.
    Omote K; Kawamata T; Nakayama Y; Kawamata M; Hazama K; Namiki A
    Anesth Analg; 2001 Jan; 92(1):233-8. PubMed ID: 11133634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of intrathecal administration of an antagonist for prostaglandin E receptor subtype EP(1) on mechanical and thermal hyperalgesia in a rat model of postoperative pain.
    Omote K; Yamamoto H; Kawamata T; Nakayama Y; Namiki A
    Anesth Analg; 2002 Dec; 95(6):1708-12, table of contents. PubMed ID: 12456444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2 contributes to the synthesis of brain-derived neurotrophic factor in primary sensory neuron in ganglion explant cultures and in a neuropathic pain model.
    Cruz Duarte P; St-Jacques B; Ma W
    Exp Neurol; 2012 Apr; 234(2):466-81. PubMed ID: 22309829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache.
    Maubach KA; Davis RJ; Clark DE; Fenton G; Lockey PM; Clark KL; Oxford AW; Hagan RM; Routledge C; Coleman RA
    Br J Pharmacol; 2009 Jan; 156(2):316-27. PubMed ID: 19154437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of binding affinity of CJ-023,423 for human prostanoid EP4 receptor.
    Murase A; Nakao K; Takada J
    Pharmacology; 2008; 82(1):10-4. PubMed ID: 18408415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.